-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Benzinga·08/25/2026 13:15:29
Listen to the news
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.